Saul N. Faust

University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre

Southampton

United Kingdom

SCHOLARLY PAPERS

11

DOWNLOADS
Rank 342

SSRN RANKINGS

Top 342

in Total Papers Downloads

91,295

SSRN CITATIONS

4

CROSSREF CITATIONS

2

Scholarly Papers (11)

1.

Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine

Number of pages: 37 Posted: 01 Feb 2021
University of Oxford - Oxford Vaccine Group, University of Siena - Institute of Global Health, University of the Witwatersrand - Vaccines and Infectious Diseases Analytics Research Unit, Federal University of São Paulo (UNIFESP), University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Oxford Vaccine Group, University of the Witwatersrand, Stellenbosch University - Family Centre for Research with Ubuntu, Soweto Clinical Trials Centre, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of the Witwatersrand - Vaccines and Infectious Diseases Analytics Research Unit, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, Liverpool School of Tropical Medicine - Department of Clinical Sciences, University of the Witwatersrand - South African Medical Research Council Vaccines and Infectious Diseases Analytical Research Unit, University of Sheffield - Department of Infection, Immunity and Cardiovascular Disease, University of Cape Town (UCT) - Centre for Lung Infection and Immunity, University of Oxford - Jenner Institute, Newcastle upon Tyne Hospitals NHS Foundation Trust - Department of Infection and Tropical Medicine, University of Oxford - Oxford Vaccine Group, GSK plc, University of Oxford - The Jenner Institute, Wits Reproductive Health & HIV Institute (WRHI), University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University of Oxford - Oxford Vaccine Group, University of Liverpool - School of Tropical Medicine, University of Bristol - Bristol Vaccine Centre, St George’s University London - St George’s Vaccine Institute, University College London - Department of Infection, University of Oxford - Clinical BioManufacturing Facility, University Hospitals Birmingham NHS Foundation Trust, University of Oxford - Oxford Vaccine Group, University of the Witwatersrand - South African Medical Research Council, Liverpool School of Tropical Medicine - Department of Clinical Sciences, AstraZeneca Pharmaceuticals, University of the Witwatersrand - South African Medical Research Council, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of the Witwatersrand - South African Medical Research Council, University of the Witwatersrand - South African Medical Research Council, University Hospitals Bristol - University Hospitals Bristol and Weston NHS Foundation Trust, NIHR UCLH Clinical Research Facility, Hull University Teaching Hospitals NHS Trust, University of Oxford - Centre for Vaccinology and Tropical Medicine, AstraZeneca Pharmaceuticals, Braziland Hospital São Rafael - Escola Bahiana de Medicina e Saúde Pública, Universidade Federal do Rio Grande do Norte (UFRN), University of Oxford - The Jenner Institute, London Northwest University Healthcare, University of Oxford - Oxford Vaccine Group, University of the Witwatersrand - Perinatal HIV Research Unit, Setshaba Research Centre, University of Oxford - Oxford Vaccine Group, Hospital Quinta D'OR, University of Oxford - Oxford Vaccine Group, Imperial College London - Department of Infectious Disease, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, Hospital Universitário de Santa Maria, University of Glasgow - College of Medical, Veterinary & Life Sciences, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, Universidade Federal do Rio Grande do Sul, Western General Hospital - Clinical Infection Research Group, MRC-University of Glasgow Centre for Virus Research, University of Cambridge - Department of Medicine, Royal Papworth HospitalUniversity of Cambridge - Heart and Lung Research Institute, Nottingham University Hospitals NHS Trust, AstraZeneca Biopharmaceuticals, AstraZeneca Pharmaceuticals, AstraZeneca Pharmaceuticals, Anuerin Bevan University Health Board, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Chinese Academy of Medical Science Oxford Institute (COI), University of Oxford - Oxford Vaccine Group and Independent
Downloads 52,404 (53)
Citation 3

Abstract:

Loading...

2.

Safety and Immunogenicity Report from the Com-COV Study – a Single-Blind Randomised Non-Inferiority Trial Comparing Heterologous And Homologous Prime-Boost Schedules with An Adenoviral Vectored and mRNA COVID-19 Vaccine

Number of pages: 45 Posted: 25 Jun 2021
University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Oxford Vaccine Group, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, Public Health England Colindale, Government of the United Kingdom - Public Health Scotland, Liverpool School of Tropical Medicine - Department of Clinical Sciences, University of Liverpool - School of Tropical Medicine, Liverpool School of Tropical Medicine - Department of Clinical Sciences, University Hospitals Birmingham NHS Foundation Trust, Public Health England - National Infection Service, University of London - Institute of Infection and Immunity, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University of Bristol - Bristol Vaccine Centre, University of Oxford - The Jenner Institute, Government of the United Kingdom - North Bristol NHS Trust, NIHR UCLH Clinical Research Facility, Public Health England - Immunisation, Hepatitis, and Blood Safety Department, University of Southampton - University Hospital Southampton NHS Foundation Trust, Nottingham University Hospitals NHS Trust, Imperial College London - National Heart & Lung Institute, University of Nottingham - Division of Epidemiology and Public Health, University of Oxford - Centre for Vaccinology and Tropical Medicine and Independent
Downloads 25,300 (218)
Citation 5

Abstract:

Loading...

3.

Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)

Number of pages: 40 Posted: 04 Feb 2021
University of Oxford - Oxford Vaccine Group, University of Oxford - Big Data Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Cambridge, University of Oxford - Oxford Vaccine Group, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Cambridge - Department of Medicine, University of Oxford - Big Data Institute, University of Oxford - The Jenner Institute, Public Health England - National Infection Service, University of Oxford - Centre for Vaccinology and Tropical Medicine, Liverpool School of Tropical Medicine - Department of Clinical Sciences, UK Biocentre, University of Sheffield - Department of Infection, Immunity and Cardiovascular Disease, University of Oxford - Oxford Vaccine Group, University of Oxford - Jenner Institute, Newcastle upon Tyne Hospitals NHS Foundation Trust - Department of Infection and Tropical Medicine, GSK plc, University of Oxford - The Jenner Institute, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University of Liverpool - School of Tropical Medicine, University of Oxford - Oxford Vaccine Group, University of Bristol - Bristol Vaccine Centre, University of Oxford - The Jenner Institute, University of Oxford - Jenner Institute, St George’s University London - St George’s Vaccine Institute, University College London - Department of Infection, University of Oxford - Clinical BioManufacturing Facility, University Hospitals Birmingham NHS Foundation Trust, University of Oxford - Oxford Vaccine Group, Public Health England - National Infection Service, University of London - Institute of Infection and Immunity, Queen Elizabeth University Hospital, Liverpool School of Tropical Medicine - Department of Clinical Sciences, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University Hospitals Bristol - University Hospitals Bristol and Weston NHS Foundation Trust, NIHR UCLH Clinical Research Facility, Hull University Teaching Hospitals NHS Trust, Genomics England, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute, London Northwest University Healthcare, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, Imperial College London - Department of Infectious Disease, University of Oxford - Oxford Vaccine Group, University of Glasgow - College of Medical, Veterinary & Life Sciences, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, Western General Hospital - Clinical Infection Research Group, MRC-University of Glasgow Centre for Virus Research, Royal Papworth HospitalUniversity of Cambridge - Heart and Lung Research Institute, Nottingham University Hospitals NHS Trust, AstraZeneca Biopharmaceuticals, AstraZeneca Pharmaceuticals, Anuerin Bevan University Health Board, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Chinese Academy of Medical Science Oxford Institute (COI), University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, Independent and Independent
Downloads 11,021 (964)
Citation 26

Abstract:

Loading...

4.

Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against COVID-19: COVAC1, a Phase I, Dose-Ranging Trial

Number of pages: 34 Posted: 16 Jun 2021
Imperial College London - Department of Infectious Disease, Imperial College London - Department of Infectious Disease, University College London - MRC Clinical Trials Unit, NIHR UCLH Clinical Research Facility, Imperial College London, NIHR Imperial Clinical Research Facility, University College London - MRC Clinical Trials Unit, Imperial College London - Department of Infectious Disease, Imperial College London - Department of Infectious Disease, Imperial College London, Imperial College London, University College London Hospitals NHS Foundation Trust - Department of Clinical Virology, University College London, Government of the United Kingdom - Chelsea and Westminster Hospital NHS Foundation Trust, Imperial College London, NIHR Imperial Clinical Research Facility, NIHR Imperial Clinical Research Facility, NIHR Imperial Clinical Research Facility, NIHR Imperial Clinical Research Facility, NIHR Imperial Clinical Research Facility, NIHR Imperial Clinical Research Facility, NIHR Imperial Clinical Research Facility, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University of Surrey - Surrey Clinical Research Centre, St George’s University London - St George’s Vaccine Institute, Imperial College London - Department of Infectious Disease, Imperial College London - Section of Virology, University College London - MRC Clinical Trials Unit, University College London - MRC Clinical Trials Unit and Imperial College London - Department of Infectious Disease
Downloads 1,539 (24,260)

Abstract:

Loading...

5.

Safety and Immunogenicity of the ChadOx1 nCoV-19 (AZD1222) Vaccine in Children Aged 12-17 Years: A Preliminary Report of a Phase 2, Single-Blind, Randomised Controlled Trial (COV006)

Number of pages: 43 Posted: 20 Dec 2021
University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of London - Institute of Infection and Immunity, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, Independent, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, Independent, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Oxford Vaccine Group and Independent
Downloads 413 (140,225)

Abstract:

Loading...

ChAdOx1 nCoV-19, AZD1222, Safety, Immunogenicity, Adolescent, COVID-19

6.

Efficacy of Nirsevimab Over 6 Months: A 180-Day Endpoint Analysis from the HARMONIE Study, a Randomized Phase IIIb Trial

Number of pages: 15 Posted: 23 Oct 2024
University of Southampton, University of Oxford, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, Université de Lille, Children’s Hospital Horst-Schmidt-Kliniken Wiesbaden, Liverpool School of Tropical Medicine - Department of Clinical Sciences, Liverpool School of Tropical Medicine, Gemeinschaftspraxis für Kinder und Jugendmedizin, Association Clinique et Thérapeutique Infantile du Val-de-Marne (ACTIV), Charles Nicolle University Hospital of Tunis, Sanofi, Sanofi, Sanofi, Sanofi, Sanofi, Sanofi, Sanofi, University of Paris-Saclay - Division of Pediatrics and Neonatal Critical Care, University of Nottingham, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre and Independent
Downloads 192 (321,753)

Abstract:

Loading...

Respiratory Syncytial Virus (RSV), Infant Lower Respiratory Tract Infections (LRTI), Nirsevimab, Prophylaxis, Infant Hospitalization

7.

Oral Valganciclovir Initiated Beyond One Month of Age for the Treatment of Sensorineural Hearing Loss Caused by Congenital Cytomegalovirus Infection

Number of pages: 30 Posted: 03 Mar 2023
University of Alabama at Birmingham, University of Alabama at Birmingham, University of Alabama at Birmingham, University of Alabama at Birmingham, University Hospitals Bristol - University Hospitals Bristol and Weston NHS Foundation Trust, Newcastle Upon Tyne Hospitals NHS Foundation Trust, University College London - Infection, Immunity and Inflammation Research & Teaching Department, University College London - Infection, Immunity and Inflammation Research & Teaching Department, Children's National Hospital - Children's Research Institute, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University of Southampton, The University of Manchester - Manchester University NHS Foundation Trust, University of Rochester, Levine Children's Hospital, St George’s University Hospitals NHS Foundation Trust, Baylor College of Medicine, Heartlands Hospital, Ohio State University (OSU) - Nationwide Children's Hospital, Sheffield Children’s Hospital, University of Oxford - Department of Paediatrics, Alpert Medical School of Brown University, University of Washington, University of Alabama at Birmingham and University College London
Downloads 139 (403,469)

Abstract:

Loading...

Congenital Cytomegalovirus, Valganciclovir, Antiviral, Hearing Loss, Sensorineural, Infant, Toddler, Audiology

8.

The Platform Trial in COVID-19 Priming and Boosting (PICOBOO): The Immunogenicity, Reactogenicity, and Safety of Different COVID-19 Vaccinations Administered as a Second Booster (Fourth Dose) in Azd1222 Primed Individuals Aged 50-<70 Years Old

Number of pages: 13 Posted: 07 May 2024
Perth Children’s Hospital - Telethon Kids Institute, Perth Children’s Hospital - Telethon Kids Institute, University of Tasmania - School of Health Sciences and School of Medicine, Royal Melbourne Institute of Technolog (RMIT University), University of Adelaide - Vaccinology and Immunology Research Trials Unit, The University of Sydney, Perth Children's Hospital - Department of Infectious Diseases, Perth Children’s Hospital - Telethon Kids Institute, Perth Children’s Hospital - Wesfarmer's Centre for Vaccines and Infectious Diseases, University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza, University of Melbourne - Department of Microbiology and Immunology (DMI), Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, at The Peter Doherty Institute for Infection and Immunity, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, Perth Children’s Hospital - Telethon Kids Institute, Perth Children’s Hospital - Telethon Kids Institute, Perth Children’s Hospital - Telethon Kids Institute, Charles Darwin University - Menzies School of Health Research and The University of Western Australia
Downloads 93 (540,770)

Abstract:

Loading...

Adaptive platform trial, COVID-19, vaccines, Bayesian, immunisation, policy

9.

Immunocompromised Children and Young People Are at No Increased Risk of Severe COVID-19

Number of pages: 28 Posted: 27 Jul 2021
University Hospital Southampton NHS Trust - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University of Southampton - Faculty of Medicine and Institute for Life Sciences, University Hospital Southampton NHS Foundation Trust - NIHR Applied Research Collaboration Wessex, National Institute for Health Research (NIHR) - Nottingham Biomedical Research Centre, University of Nottingham - School of Life Sciences, Nottingham University Hospitals NHS Trust - NIHR Nottingham Biomedical Research Centre, University of Nottingham - School of Life Sciences, University of Nottingham - School of Life Sciences, University Hospital Southampton NHS Trust - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Trust - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Trust - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Trust - Paediatric Medicine, University Hospital Southampton NHS Trust - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Trust - NIHR Southampton Clinical Research Facility and Biomedical Research Centre and Independent
Downloads 85 (571,470)

Abstract:

Loading...

SARS-CoV-2, COVID-19, children, immunocompromised

10.

The Platform Trial in COVID-19 Priming and BOOsting (PICOBOO): The Immunogenicity, Reactogenicity, and Safety of Licensed COVID-19 Vaccinations Administered as a Second Booster in BNT162b2 Primed Individuals Aged 18-<50 and 50-<70 Years Old

Number of pages: 39 Posted: 08 Jul 2024
Perth Children’s Hospital - Telethon Kids Institute, Perth Children’s Hospital - Telethon Kids Institute, University of Tasmania - School of Health Sciences and School of Medicine, Royal Melbourne Institute of Technolog (RMIT University), University of Adelaide - Vaccinology and Immunology Research Trials Unit, The University of Sydney, Perth Children's Hospital - Department of Infectious Diseases, Perth Children’s Hospital - Telethon Kids Institute, Perth Children’s Hospital - Wesfarmer's Centre for Vaccines and Infectious Diseases, University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza, University of Melbourne - Department of Microbiology and Immunology (DMI), Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, at The Peter Doherty Institute for Infection and Immunity, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, Perth Children’s Hospital - Telethon Kids Institute, Perth Children’s Hospital - Telethon Kids Institute, Perth Children’s Hospital - Telethon Kids Institute, Charles Darwin University - Menzies School of Health Research and The University of Western Australia
Downloads 65 (661,835)

Abstract:

Loading...

COVID-19, Booster Vaccines, Immunogenicity, adaptive platform trial, health policy.

11.

COVAC1 Phase 2a Expanded Safety and Immunogenicity Study of a Self-Amplifying RNA Vaccine Against SARS-CoV-2

Number of pages: 33 Posted: 27 Sep 2022
University College London - MRC Clinical Trials Unit, Imperial College London - Department of Infectious Disease, Imperial College London - Department of Infectious Disease, Imperial College London - Department of Infectious Disease, University College London - MRC Clinical Trials Unit, St George’s University London - St George’s Vaccine Institute, Government of the United Kingdom - Department of HIV/GUM, Government of the United Kingdom - Department of HIV/GUM, NIHR Imperial Clinical Research Facility - NIHR Imperial Biomedical Research Centre, St George’s University London - St George’s Vaccine Institute, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, Imperial College London - Section of Virology, St George’s University London - St George’s Vaccine Institute, University of Surrey - Surrey Clinical Research Centre, Imperial College London - Department of Infectious Disease, NIHR UCLH Clinical Research Facility, Imperial College London - Department of Infectious Disease, Chelsea and Westminster Hospital NHS FT, Imperial College London - Department of Infectious Disease, NIHR Imperial Clinical Research Facility - NIHR Imperial Biomedical Research Centre, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton - NIHR Southampton Biomedical Research Centre, University College London - Comprehensive Biomedical Research Centre, University of Surrey - Surrey Clinical Research Centre, Imperial College London - Department of Infectious Disease, University of Surrey - Surrey Clinical Research Centre, University College London - Comprehensive Biomedical Research Centre, University College London - MRC Clinical Trials Unit, University College London - MRC Clinical Trials Unit and Imperial College London - Department of Infectious Disease
Downloads 44 (785,820)

Abstract:

Loading...

SARS-CoV-2, vaccination, self-amplifying RNA, saRNA, immune response